Carrillo ER, Carvajal RR

Idioma: Español
Referencias bibliográficas: 98
Paginas: 206-222
Archivo PDF: 111.67 Kb.

RESUMEN

La sepsis es la respuesta inflamatoria sistémica a la infección, su incidencia va en aumento y se relaciona con elevada mortalidad. Es secundaria a la interacción de la respuesta inmunitaria innata entre microorganismos y sus componentes, lo que resulta en la síntesis de citocinas pro-inflamatorias, radicales libres de oxígeno y otros mediadores que inducen, en conjunto, daño endotelial y coagulopatía, mismos que evolucionan a trombosis microvascular, hipoxia y disfunción orgánica múltiple. El diagnóstico temprano y oportuno es fundamental. El tratamiento está dirigido al control del disparador, al uso temprano y oportuno de antibióticos, reanimación dirigida por metas, control metabólico, modulación inmunoinflamatoria y otras medidas de sostén.

REFERENCIAS (EN ESTE ARTÍCULO)

1. http://www.inegi.gob.mx/est/contenidos/espanol/tematicos/mediano/med.asp?t=mpob45&c=3222.

2. Increase in national hospital discharge survey rates for septicemia-United States, 1979-1987. MMWR Morb Mortal Wkly Rep 1990;39:31-34.

3. Angus DC, Wax RS. Epidemiology of sepsis: an update. Crit Care Med 2001;29:109-16.

4. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome and associated costs of care. Crit Care Med 2001;29:1303-10.

5. Bone RC. The sepsis syndrome: definition and general approach to management. Clin Chest Med 1996;17:75-82.

6. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines of the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-74.

7. Abraham E, Matthay MA, Dinarello CA, et al. Consensus conference definitions for sepsis, septic shock, acute lung injury, and acute respiratory distress syndrome: time for a reevaluation. Crit Care Med 2000;28:232-5.

8. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;31:1250-6.

9. Vincent JL, Wendon J, Groeneveld J, et al. The PIRO concept: O is for organ dysfunction. Crit Care Med 2003;3:260-4.

10. Opal M. Severe sepsis and septic shock: defining the clinical problem. Scand J Infect Dis 2003;9:529-34.

11. Carrillo ER, Nuñez FN. Systemic inflammatory response syndrome: new concepts. Gac Med Mex 2001;137:127-34.

12. Carrillo ER. Modulación genética de la respuesta inflamatoria sistémica en sepsis. Rev Asoc Mex Med Crit Ter Int 2001;15:92-95.

13. Janeway JCA, Medzhitov R. Introduction: the role of innate immunity in the adaptive innate response. Semin Immunol 1998;10:349-50.

14. Carrillo ER, González JA. Inflamación – endotelio – coagulación en sepsis. Conceptos actuales. Cir Ciruj 2002;70:433-41.

15. Carrillo ER. Inmunidad innata, receptores Toll y sepsis. Cir Ciruj 2003;71:252-8.

16. Cines DB, Pollak ES, Buck CA, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998;91:3527-61.

17. Cerik H, Sacha Z. The edothelium in sepsis: source of and a target for inflammation. Crit Care Med 2001;29:S21-S27.

18. Mavrommatis AC, Theodoridis T, Orfanodoui A, et al. Coagulation system and platelets are fully activated in uncomplicated sepsis. Crit Care Med 2000;28:451-7.

19. Boldt J, Papsdorf M, Rothe A, et al. Changes of the hemostatic network in critically ill patients: is there a difference between sepsis, trauma, and neurosurgery patients? Crit Care Med 2000;28:445-50.

20. De Jonge E, Levi M, Van der Poll T. Coagulation abnormalities in sepsis: relation with inflammatory responses. Crit Care Med 2000;6:317-22.

21. López-Aguirre Y, Páramo JA. Endothelial cell and hemostatic activation in relation to cytokines in patients with sepsis. Thromb Res 1999;94:95-101.

22. Vervloet MG, Thijs LG, Jack CE. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock. Semin Thromb Hemost 1998;24:33-44.

23. Marshall JC. Inflammation, coagulopathy, and the pathogenesis of multiple organ system. Crit Care Med 2001;29:S99-S106.

24. Sessler C, Windsor A, Scwartz M. Circulating ICAM-1 is increased in septic shock. Am J Respir Crit Care Med 1995;151:1420-7.

25. Xu H, Gonzalo JA, St Pierre Y, et al. Leukocytosis and resistance to septic shock in intercellular adhesion molecule 1-deficient mice. J Exp Med 1994;180:95-109.

26. Zimmerman GA, Prescott SM, McIntyre TM. Endothelial cell interactions with granulocytes: tethering and signaling molecules. Immunol Today 1992;13:93-100.

27. Kyriakides C, Austen WG Jr, Wang Y, et al. Neutrophil mediated remote organ injury after lower torso ischemia and reperfusion is selectin and complement dependent. J Trauma 2000;48:32-38.

28. Wolbink GJ, Bossink AW, Groeneveld AB, et al. Complement activation in patients with sepsis is in part mediated by C-reactive protein. J Infect Dis 1998;177:81-87.

29. Lagrand WK, Visser CA, Hermens WT, et al. C-reactive protein as a cardiovascular risk factor. More than an epiphenomenon? Circulation 1999;100:96-102.

30. Corrigan JJ, Ray WL, May N. Changes in the blood coagulation system associated with septicemia. N Engl J Med 1968;279:851-6.

31. McGilvray ID, Rotstein OD. Role of the coagulation system in the local and systemic inflammatory response. World J Surg 1998;22:179-86.

32. Faust NS, Heyderman SR, Levin M. Coagulation in severe sepsis: a central role for thrombomodulin and activated protein C. Crit Care Med 2001;29:S62-S68.

33. Yan SB, Dhainaut JF. Activated protein C versus protein C in severe sepsis. Crit Care Med 2001;29:S69-S74.

34. Gordon B, Artigas A, Dellinger P, et al. Clinical expert round table discussion at the Margaux Conference on Critical Illness: the role of activated protein C in severe sepsis. Crit Care Med 2001;29:S75-S77.

35. Fisher JC, Yan BS. Protein C levels as a prognostic indicator of outcome in sepsis and related diseases. Crit Care Med 2000;28:S49-S56.

36. Balk RA. Pathogenesis and management of multiple organ dysfunction or failure in severe sepsis and septic shock. Crit Care Clin 2000;16:337-52.

37. Bistrian BR. Acute phase proteins and the systemic inflammatory response syndrome. Crit Care Med 1999;27:452-3.

38. Heumann D, Glauser MP, Calandra T. Molecular basis of host-pathogen interaction in septic shock. Curr Opin Microbiol 1998:149-55.

39. Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European prevalence of infection in intensive care (EPIC) study. EPIC International Advisory Committee. JAMA 1995;274:639-44.

40. Vincent JL, Anaissie E, Bruining H, et al. Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care. Intensive Care Med 1998;24:206-16.

41. Richards MJ, Edwards JR, Culver DH, et al. National Nosocomial Infections Surveillance System: nosocomial infections in medical intensive care units in the United States. Crit Care Med 1999;27:887-92.

42. Appelgren P, Hellstrom I, Wetzberg E, et al. Risk factors for nosocomial intensive care infection: a long-term prospective analysis. Acta Anaesthesiol Scand 2001;45:710-9.

43. Reinhart K, Bayer O, Brunkhorst F, Meisner M. Markers of endothelial damage in organ dysfunction and sepsis. Crit Care Med 2002;30:S302-S12.

44. Boldt J, Muller M, Kuhn D, et al. Circulating adhesion molecules in the critically ill: a comparison between trauma and sepsis patients. Intensive Care Med 1996;22:122-8.

45. Fourrier F, Chopin C, Goudemand J, et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992;101:816-23.

46. Pettila V, Hynninen M, Takkunen O, et al. Predictive value of procalcitonin and interleukin 6 in critically ill patients with suspected sepsis. Intensive Care Med 2002; 28:1220-5.

47. Panacek EA, Kaul M. IL-6 as a marker of excessive TNF-a activity in sepsis. Sepsis 1999; 3:65-73.

48. Povoa P, Almeida E, Moreira P, et al. C-reactived protein as an indicator of sepsis. Intensive Care Med 1998;24:1052-6.

49. Ugarte H, Silva E, Mercan D, et al. Procalcitonin usage as a marker of infectious in the ICU. Crit Care Med 1999;27:498-504.

50. Weinstein MP, Reller LP, Murphy JR, et al. The clinical significance of positive blood cultures: a comprehensive analysis of 500 episodes of bacteremia and fungemia in adults. I. Laboratory and epiedmiologic observations. Rev Infect Dis 1983;5:35-53.

51. McCabe WR, Jackson GG. Gram negative bacteremia. Arch Intern Med 1962;110:92-100.

52. Kreger BE, Craven DE, McCabe WR. Gram negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients. Am J Med 1980;68:344-55.

53. Leibovici L, Shraga I, Drucker M, et al. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998;244:379-86.

54. Niederman MS, Fein AM. The adult respiratory distress syndrome, and nosocomial pneumonia: a common clinical sequence. Clin Chest Med 1990;11:633-56.

55. Brismar B, Malmborg AS, et al. Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections. Antimicrob Agents Chemother 1997:36:2766-733.

56. Kollef M, Niederman M. Antimicrobial resistance in the ICU: the time for action is now. Crit Care Med 2001;29:N63.

57. Niederman MS. Appropriate use of antimicrobial agents: challenges and strategies for improvement. Crit Care Med 2003;31:608-16.

58. Leone M, Bourgoin A, Cambon S, et al. Empirical antimicrobial therapy of septic shock patients: adequacy and impact on the outcome. Crit Care Med 2003;31:462-7.

59. Kollef MH. Is there a role for antibiotic cycling in the intensive care unit? Crit Care Med 2001;29:N135-N42.

60. Paterson DL. Restrictive antibiotic policies are appropriate in intensive care units. Crit Care Med 2003;31:S25-S28.

61. Niederman MS. Impact of antibiotic resistance on clinical outcomes and the cost of care. Crit Care Med 2001;29:N114-N20.

62. Wey SB, Mori M, et al. Risk factors for hospital-acquired candidemia: a matched case-control study. Arch Intern Med 1989;149:2349-53.

63. Jimenez MF, Marshall JC. Source control in the management of sepsis. Intensive Care Med 2001;27:S49-S62.

64. Moss RL, Musemeche CA, Kosloske AM. Necrotizing fascitis in children: prompt recognition and aggressive therapy improve survival. J Pediatr Surg 1996;31:1142-6.

65. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-77.

66. Hollenberg SM, Ahrens TS, Astiz ME, et al. Practice parameters for hemodynamic support of sepsis in adult patients. Crit Care Med 1999;27:639-60.

67. LeDoux D, Astiz ME, Carpati CM, et al. Effects of perfusion pressure on tissue perfusion in septic shock. Crit Care Med 2000;28:2729-32.

68. Martin C, Viviand X, Leone M, et al. Effect of norepinephrine on the outcome of septic shock. Crit Care Med 2000;28:2758-65.

69. Choi PTL, Yip G, Quinonez LG, et al. Crystalloids vs. colloids in fluid resuscitation: a systematic review. Crit Care Med 1999;27:200-10.

70. Cook D, Guyatt G. Colloid use for fluid resuscitation: evidence and spin. Ann Intern Med 2001;135:205-8.

71. Schierhout G, Roberts I. Fluid resuscitation with colloid or crystalloid solutions in critically ill patients: a systematic review of randomized trials. BMJ 1998;316:961-4.

72. De Backer D, Creteur J, Silva E, et al. Effects of dopamine, norepinephrine, and epinephrine on the splanchnic circulation in septic shock: Which is best? Crit Care Med 2003;31:1659-67.

73. Holmes CL, Patel BM, Russell JA, et al. Physiology of vasopressin relevant to management of septic shock. Chest 2001;120:989-1002.

74. Carrillo ER, Carvajal RR, Hernández AC. Vasopresina: una nueva alternativa terapéutica en el enfermo grave. Rev Asoc Mex Med Crit Int 2003;5:162-71.

75. Bellomo R, Chapman M, Finfer S, et al. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 2000;356:2139-43.

76. Kellum J, Deckler J. Use of dopamine in acute renal failure: a meta-analysis. Crit Care Med 2001;29:1526-31.

77. Hébert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion in critical care. N Engl J Med 1999;340:409-17.

78. Marik PE, Sibbald WJ. Effect of stored-blood transfusion on oxygen delivery in patients with sepsis. JAMA 1993;269:3024-9.

79. Lorente JA, Landín L, De Pablo R, et al. Effects of blood transfusion on oxygen transport variables in severe sepsis. Crit Care Med 1993;21:1312-8.

80. Brochard L, Roudat-Thoraval F, Roupie E, et al. Tidal volume reduction for prevention of ventilator-induced lung injury in acute respiratory distress syndrome. The Multicenter Trial Group on Tidal Volume Reduction in ARDS. Am J Respir Crit Care Med 1998; 158:1831-8.

81. Brower RG, Shanholtz CB, Fessler HE, et al. Prospective, randomized, controlled clinical trial comparing traditional versus reduced tidal volume ventilation in acute respiratory distress syndrome patients. Crit Care Med 1999;27:1492-8.

82. Brower RG, Fessler HE. Mechanical ventilation in acute lung injury and acute respiratory distress syndrome. Clin Chest Med 2000;21:491-510.

83. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001;345:1359-67.

84. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288:862-71.

85. Briegel J, Forst H, Haller M, et al. Stress doses of hydrocortisone reverse hyperdinamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med 1999;27:723-32.

86. Kanji S, Devlin J, Piekos K, Racin E. Recombinant human activated protein C, drotrecogin alfa (activated): a novel therapy for severe sepsis. Pharmacotherapy 2001;21:1389-402.

87. Vincent JL, Angus DC, Artigas A, Kalil A, et al. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med 2003;31834-40.

88. Hotchkiss RS, Karl IE. The patophysiology and treatment of sepsis. N Engl J Med 2003;348:138-51.

89. Laterre PF, Wittebole X. Clinical review: drotrecogin alfa (activated) as adjunctive therapy for severe sepsis – practical aspects at the bedside and patient identification. Crit Care 2003;7:445-50.

90. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.

91. Natanson C, Hoffman WD, Zuffredini AF, Eichacker PQ, et al. Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Intern Med 1994;120:771-83.

92. Zeni F, Freeman B, Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med 1997;25:1095-100.

93. Panacek E, Marshall JC, Fischkoff S, et al. Neutralization of TNF by a monoclonal antibody improves survival and reduces organ dysfunction in human sepsis: results of the MONARCS trial. Chest 2000;118(Suppl):S88.

94. Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor-a in patients with sepsis syndrome. JAMA 1995;273:934-41.

95. Natanson C, Esosito CJ, Banks SM. The siren’s songs of confirmatory sepsis trials: selection bias and sampling error. Crit Care Med 1998;26:1927-31.

96. Reinhart K, Wiegand-Löhnert C, Grimminger F, et al. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 1996;24:733-42.

97. Fisher CJ Jr, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor Fc fusion protein. N Engl J Med 1996;334:1697-702.

98. Dellinger RP, Carlet JM, Masur H, Gerlach H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004;32:858-72.